Rosiglitazone Recall
Links shared publicly online about this topic
Reanalysis of rosiglitazone meta-analysis raises questions
theheart.org — “A new analysis of the same 42 trials, but using a number of different statistical methods to account for all the zero events, found no significant increase in either MI or CV death and highlights flaws in the original study. In response, Nissen counters that the report is now neither useful nor relevant in the wake of the FDA hearing. The FDA panel chair says the whole saga highlights the need for drug-approval reform. (Diamond G et al. Ann Intern Med; published online before print August 6, 200” View full resource at theheart.org
Most Recently Shared on July 13, 2010 at 10:19 pm By:
#Avandia - Last minute question Kaul to Nissen! Recall Kaul co-authored rosiglitazone critique of Nissen's 2007 paper: http://bit.ly/dwD8yi
Diabetes Drug Avandia Targeted by FDA Reviewers on Safety - ABC News
abcnews.go.com — “The end of GlaxoSmithKline's multi-billion dollar diabetes drug Avandia could be drawing near, if two Food and Drug Administration reviewers are successful in their bid to have the drug pulled from the market because of its link to major cardiac events.” View full resource at abcnews.go.com
Most Recently Shared on February 23, 2010 at 3:06 pm By:
Michael Breen Emergency Physician, Physician, and Doctor
Avandia Recall Will Affect Millions With DM. Media will want local expert comment. Provide it! http://bit.ly/aVwy9o #hcmktg #hcsm
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
Shelley Wood
Managing editor for heartwire on theheart.org--the most authoritative, balanced, and insightful cardiovascular disease news online. http://is.gd/nHJ4
-
Michael Breen
Former Chicago TV Physician Who Now Markets For Practices, Hospitals, and Medical Device Companies
Advertisement
